052317
Thrombopoietin R (Tpo R)
Size
£889.00
- SKU:
- 052317
- Purity:
- Purified by immunoaffinity chromatography. Endotoxin: ≤0.1EU/ug (LAL).
- Storage Conditions:
- -20°C
- Supplier:
- United States Biological
- Host:
- Goat
- Immunogen:
- Recombinant protein corresponding to Gln26-Tyr423 from human Thrombopoietin R, expressed in NS0 cells
- Format:
- Supplied as a lyophilized powder in PBS, 5% trehalose. Reconstitute with 500ul sterile PBS.
- Extra Details:
- Thrombopoietin receptor (Tpo R), also known as myeloproliferative leukemia protein (c-mpl), is a 95kD type I transmembrane protein that is a member of the type I cytokine receptor family within the hematopoietin/cytokine receptor superfamily (1‑4). The 635 amino acid (aa) full-length human Tpo R contains a 25 aa signal sequence, a 466 aa extracellular domain with a ligand binding domain and two fibronectin type III domains, a transmembrane (TM) domain and a cytoplasmic domain. The extracellular domain of human Tpo R shares 78%, 76%, 81%, 82% and 80% aa identity with mouse, rat, bovine, canine and equine Tpo R, respectively. Humans produce three distinct mRNA species; a P-form, a K-form, and a truncated form (Mpl-tr) lacking a TM domain (3‑7). The P-form encodes the full-length receptor. The Mpl-tr form, which is expressed in both human and mouse, is intracellular and targets the P-form for degradation (5, 6). The 579 aa K-form has an alternate cytoplasmic domain, but does not dimerize with, or inhibit, the P-form (7). Thrombopoietin (Tpo) is a key regulator of megakaryocytopoiesis, thrombopoiesis and hematopoietic stem cell self-renewal, as reflected by expression of the Tpo R on megakaryocytes, platelets and hematopoietic progenitors (2, 8). Receptor dimerization occurs upon Tpo binding and initiates signaling through the Ras/MAP and JAK/STAT pathways (1, 2). Internalization and degradation of Tpo following Tpo R binding serves to downregulate circulating Tpo (9). Tpo R expressed at low levels on endothelial cells does not appear to contribute to regulation of Tpo (10). Inactivating mutations of Tpo R cause thrombocytopenia, and absence of functional Tpo R is lethal in humans, but not mice. Other mutations, including an activating change in the TM domain, can cause thrombocytosis (11, 12). Applications: Suitable for use in Western Blot and Neuralization. Other applications not tested. Recommended Dilutions: Western Blot: 0.1ug/ml with recombinant human Thrombopoietin R/Tpo R Neutralization: Measured by its ability to neutralize Thrombopoietin/Tpo-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 0.100‑1.50μg/mL in the presence of 10ug/ml recombinant human thrombopoietin/Tpo. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
- Shipping Conditions:
- Blue Ice